JPH02500362A - エストロゲン効果を有する製剤 - Google Patents
エストロゲン効果を有する製剤Info
- Publication number
- JPH02500362A JPH02500362A JP87505402A JP50540287A JPH02500362A JP H02500362 A JPH02500362 A JP H02500362A JP 87505402 A JP87505402 A JP 87505402A JP 50540287 A JP50540287 A JP 50540287A JP H02500362 A JPH02500362 A JP H02500362A
- Authority
- JP
- Japan
- Prior art keywords
- formulation according
- administered
- formulation
- present
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 41
- 230000001076 estrogenic effect Effects 0.000 title claims description 15
- 206010067572 Oestrogenic effect Diseases 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 claims description 80
- 238000009472 formulation Methods 0.000 claims description 76
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 44
- 241000700159 Rattus Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 18
- 102000009151 Luteinizing Hormone Human genes 0.000 description 16
- 108010073521 Luteinizing Hormone Proteins 0.000 description 16
- 229940040129 luteinizing hormone Drugs 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 206010062767 Hypophysitis Diseases 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 210000003635 pituitary gland Anatomy 0.000 description 13
- 229940088597 hormone Drugs 0.000 description 12
- 239000005556 hormone Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 230000035935 pregnancy Effects 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- 210000003754 fetus Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000012173 estrus Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000026234 pro-estrus Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 206010062662 Uterine mass Diseases 0.000 description 6
- 229940028334 follicle stimulating hormone Drugs 0.000 description 6
- 230000027758 ovulation cycle Effects 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 231100000535 infertility Toxicity 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 201000005670 Anovulation Diseases 0.000 description 4
- 206010002659 Anovulatory cycle Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 231100000552 anovulation Toxicity 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000004720 fertilization Effects 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000583 progesterone congener Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000003687 estradiol congener Substances 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 210000003905 vulva Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000001158 estrous effect Effects 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000000624 ovulatory effect Effects 0.000 description 2
- 229940072033 potash Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000378 teratogenic Toxicity 0.000 description 2
- 230000003390 teratogenic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- KINNMTBWIQCDPS-UHFFFAOYSA-N 1,1,3-trimethyl-2-[3,7,12,16-tetramethyl-18-(2,2,6-trimethylcyclohexyl)octadecyl]cyclohexane Chemical class CC1CCCC(C)(C)C1CCC(C)CCCC(C)CCCCC(C)CCCC(C)CCC1C(C)CCCC1(C)C KINNMTBWIQCDPS-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 241000510609 Ferula Species 0.000 description 1
- 208000020848 Genetic infertility Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 208000035175 Oligomenorrhea Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046792 Uterine hypotonus Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000000566 mammotropic effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1987/000065 WO1988009164A1 (en) | 1987-05-29 | 1987-05-29 | Pharmaceutical preparation having oestrogen action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02500362A true JPH02500362A (ja) | 1990-02-08 |
Family
ID=21617114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP87505402A Pending JPH02500362A (ja) | 1987-05-29 | 1987-05-29 | エストロゲン効果を有する製剤 |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPH02500362A (enrdf_load_html_response) |
| CH (1) | CH672251A5 (enrdf_load_html_response) |
| DE (1) | DE3790958T1 (enrdf_load_html_response) |
| FR (1) | FR2621485B1 (enrdf_load_html_response) |
| GB (1) | GB2213062B (enrdf_load_html_response) |
| WO (1) | WO1988009164A1 (enrdf_load_html_response) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522043A (ja) * | 2003-04-04 | 2006-09-28 | インデナ エッセ ピ ア | フェルラ属植物からフェルチニンを製造する方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2251249A1 (de) * | 1972-10-19 | 1974-05-02 | Hoechst Ag | Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten |
| CA1063935A (en) * | 1975-04-21 | 1979-10-09 | Frederick G. Wheeler | Antacid tablets and processes for their preparation |
| FR2481270A1 (fr) * | 1980-04-24 | 1981-10-30 | Roussel Uclaf | Nouveaux derives substitues de l'acide 4-phenyl 4-oxo 2-hydroxy butanoique, procede pour leur preparation et applications comme medicaments |
-
1987
- 1987-05-29 CH CH3458987A patent/CH672251A5/de not_active IP Right Cessation
- 1987-05-29 JP JP87505402A patent/JPH02500362A/ja active Pending
- 1987-05-29 WO PCT/SU1987/000065 patent/WO1988009164A1/ru active Application Filing
- 1987-05-29 DE DE19873790958 patent/DE3790958T1/de not_active Withdrawn
- 1987-10-07 FR FR8713841A patent/FR2621485B1/fr not_active Expired - Fee Related
-
1989
- 1989-01-26 GB GB8901641A patent/GB2213062B/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522043A (ja) * | 2003-04-04 | 2006-09-28 | インデナ エッセ ピ ア | フェルラ属植物からフェルチニンを製造する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2213062B (en) | 1990-03-14 |
| GB2213062A (en) | 1989-08-09 |
| FR2621485A1 (fr) | 1989-04-14 |
| FR2621485B1 (fr) | 1990-02-16 |
| DE3790958T1 (de) | 1989-05-24 |
| WO1988009164A1 (en) | 1988-12-01 |
| GB8901641D0 (en) | 1989-04-05 |
| CH672251A5 (enrdf_load_html_response) | 1989-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2278925T3 (es) | Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal. | |
| Al-Said et al. | Post-coital antifertility activity of the seeds of Coriandrum sa tivum in rats | |
| Herrmann et al. | Effects of the antiprogesterone RU 486 in early pregnancy and during the menstrual cycle | |
| JP2004155779A (ja) | 更年期症の予防・治療用経口組成物 | |
| Sommerville et al. | Urinary excretion of pregnanediol in human subjects following the administration of progesterone and of pregnane-3α: 20α-diol. 1 | |
| Okwuasaba et al. | Pharmacological studies on the antifertility effects of RICOM‐1013‐J from Ricinus communis var minor and preliminary clinical studies on women volunteers | |
| Hartman et al. | THE EFFECT OF TESTOSTERONE ON THE MONKEY UTERUS AND THE ADMINISTRATION OF STEROIDAL HORMONES IN THE FORM OF DEANESLYPARKES PELLETS | |
| Hamblen | The clinical evaluation of ovarian responses to gonadotropic therapy | |
| Meguem et al. | Effects of the aqueous extract of Dicliptera verticillata on fertility and different stages of gestation in female rats | |
| JPH02500362A (ja) | エストロゲン効果を有する製剤 | |
| Obaro-Onezeyi et al. | Phytochemical screening, acute toxicity study and evaluation of the n-Hexane extract of brassica oleracea Linn. on the stages of pregnancy and parturition in experimental animals | |
| Halbe et al. | Updating the clinical experience in endometriosis–the Brazilian perspective | |
| FRANK et al. | Clinical and laboratory investigations of some of the newer sex hormone preparations | |
| Von Haam et al. | Clinical studies on stilbestrol | |
| Arowojolu | Treatment of endometriosis with depot medroxyprogesterone acetate: a preliminary experience | |
| Khosla et al. | A review on birth control: natural source as anti-fertility agents | |
| Borell | Contraceptive Methods-Their Safety, Efficacy and Acceptability | |
| Corner | Corpus Luteum Hormone | |
| Allen | The chemical and physiological properties, and clinical uses of the corpus luteum hormone, progesterone | |
| WILSON JR | The levels of prostaglandins in the uterus of nonpregnant, pregnant and progesterone-treated ewes | |
| US11058737B2 (en) | Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females | |
| Umarji et al. | Advances in the management of female infertility | |
| DARMA et al. | 63 EFFECTS OF THE METHANOL LEAF EXTRACT OF Newbouldia laevis ON OESTROGEN LEVELS DURING PREGNANCY IN RABBIT DOES IN KADUNA STATE, NIGERIA | |
| Baird et al. | Antifertility effects of antigestogens | |
| CHEUNG-LAM | STUDIES ON THE UTER0TONIC ALKALOIDS |